Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

PHASE4CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Ultra High Risk for Psychosis
Interventions
DRUG

Omega-3 fatty acids

OTHER

Placebo

Trial Locations (14)

Unknown

BioPsyC Biopsychosocial Corporation, Vienna

Department of Child and Adolescent Psychiatry, University of Tübingen, Tübingen

Schneider Children's Medical Center, Petah Tikva

Tel Hashomer The Sheba Medical Center, Ramat Gan

Fondazione Santa Lucia, Rome

Sapienza University of Rome, Rome

Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht

Institute of Clinical Medicine, University of Bergen, Bergen

Hospital Clinic de Barcelona, Barcelona

Hospital Infantil Passeig Sant Joan de Deu, Barcelona

Hospital General Universitario Gregorio Marañon, Madrid

Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria, Santander

ZKJP University Zürich, Zurich

Psychiatry, Centre for Clinical Brain Sciences, Edinburgh

All Listed Sponsors
lead

Rene Kahn

OTHER

NCT02597439 - Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe | Biotech Hunter | Biotech Hunter